Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Hanny Al-Samkari et al, published in The New England Journal of Medicine:
“Romiplostim use allows more chemotherapy to be delivered on time.
A paper in this week’s New England Journal of Medicine by Hanny Al-Samkari and colleagues reports on a double-blind study of Romiplostim vs Placebo for Chemotherapy-induced Thrombocytopenia.
84% of the Romiplostim and 36% of the Placebo group had no chemotherapy dose modifications.
All the patients had solid tumours.
We do not know if administering more chemo results in a survival advantage, since this would have required a larger trial and much longer follow-up.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al‑Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine

Other articles featuring Michael Makris on Hemostasis Today.
-
Aug 3, 2026, 16:01Your First Steps After an ITP Diagnosis – ITP Support Association
-
Aug 3, 2026, 15:33Christina Crossette-Thambiah: Scientific Excellence and Mentorship at ISTH 2026
-
Aug 3, 2026, 15:22Connie Montgomery: Why Global Support is Essential for the HFA Black Voices Initiative
-
Aug 3, 2026, 15:18Ifeanyichukwu Ifechidere: The DOAC Monitoring Masterclass
-
Aug 3, 2026, 15:02David McIntosh: UK Plasma Action – a Founder’s Reflections
-
Aug 3, 2026, 14:49Ney Carter Borges: Targeting the Gut Microbiome to Prevent Atrial Fibrillation
-
Aug 3, 2026, 13:42Immune Thrombocytopenia: Moving Beyond Platelet Counts Toward Durable Remission
-
Aug 3, 2026, 13:28Aboo Shama Khan: Pulmonary Embolism – A Medical Emergency Every Nurse Must Recognize
-
Aug 3, 2026, 13:08Ashwin Patel: Evaluating Red Cell Function Post-Treatment in SCD Patients